$-0.23
(Market cap
$464 Mln
Recently Viewed
Clear AllMarket cap
$464 Mln
Revenue (TTM)
$72 Mln
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.4
Debt to Equity
0
Book Value
$18.4
EPS
$-0.5
Face value
--
Shares outstanding
15,862,705
CFO
$-433.79 Mln
EBITDA
$-614.58 Mln
Net Profit
$-670.38 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Assembly Biosciences (ASMB)
| -17.4 | -1.7 | 0.3 | 170.0 | 33.9 | -11.4 | -8.8 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Assembly Biosciences (ASMB)
| 115.5 | 59.7 | -36.9 | -44.2 | -61.5 | -70.4 | -9.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Assembly Biosciences (ASMB)
|
28.1 | 463.8 | 72.3 | -6.1 | -14.4 | -5.1 | -- | 2.2 |
| 12.4 | 3,993.9 | 3,018.8 | 72.1 | 12.6 | -80 | 56.9 | 105.4 | |
| 40.9 | 5,228.7 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.2 | 14.1 | |
| 187.9 | 9,667.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 109.5 | |
| 73.8 | 14,879.0 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.1 | 4,910.2 | 761.4 | 99.7 | 7.3 | 15 | 56.3 | 7.6 | |
| 13.6 | 11,337.9 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.6 | 2.8 | |
| 22.4 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.1 | 7,186.6 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.5 | 1.0 | |
| 226.6 | 4,622.8 | 268.1 | 124.5 | 60.0 | 13.5 | 37.8 | 4.4 |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are... in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Read more
CEO, President & Director
Mr. Jason A. Okazaki
CEO, President & Director
Mr. Jason A. Okazaki J.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Assembly Biosciences Inc (ASMB) is $28.11 (NASDAQ) as of 24-Apr-2026 13:31 EDT. Assembly Biosciences Inc (ASMB) has given a return of 33.93% in the last 3 years.
Since, TTM earnings of Assembly Biosciences Inc (ASMB) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-62.28
|
1.84
|
|
2024
|
-2.58
|
3.11
|
|
2023
|
-0.07
|
0.11
|
|
2022
|
-0.06
|
0.06
|
|
2021
|
-0.08
|
0.06
|
The 52-week high and low of Assembly Biosciences Inc (ASMB) are Rs 39.71 and Rs 10.41 as of 25-Apr-2026.
Assembly Biosciences Inc (ASMB) has a market capitalisation of $ 464 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Assembly Biosciences Inc (ASMB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.